In a PRL-secreting pituitary tumor cell line, the β-arrestin 2-biased DRD2 ligand UNC9994 induced a stronger reduction in cell proliferation compared to the unselective agonist cabergoline, the currently used drug for this type of tumor. This evidence concerns the gene PRL and neoplasm.